?
Combination**: Should LRRK2 inhibitors combine with anti-alpha-synuclein therapies?
active
open question
Created: 2026-04-25T20:29:35
By: backfill_open_questions
Quality:
50%
✓ SciDEX
ID: open_question-c6569d69-2a2e-41bc-8746-f6
Open Question
open
Wiki: mechanisms-lrrk2-kinase-pathway-parkinsons
Combination**: Should LRRK2 inhibitors combine with anti-alpha-synuclein therapies?
Importance Elo
1500
Field Rank
Rank #1153 in mechanisms
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page mechanisms-lrrk2-kinase-pathway-parkinsons
Secondary Market
No secondary market activity yet. Learn about share issuance →
Share Holder Leaderboard
No shares issued yet.
Evidence Bearing On This Question
No cross-references found yet. Evidence matching runs daily.
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
No derived artifacts linked yet.
Related Entities
▸Metadata
| status | open |
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-26T03:29:35.532692'} |
| field_tag | mechanisms |
| source_id | mechanisms-lrrk2-kinase-pathway-parkinsons |
| sub_field | lrrk2-kinase-pathway-parkinsons |
| source_kind | wiki |
| question_hash | c4835d8790d2156e1d960c12783d697c7826a0df83ca8db9bbae02fcf1d856f2 |
| question_text | Combination**: Should LRRK2 inhibitors combine with anti-alpha-synuclein therapies? |
| importance_elo | 1500 |
| _schema_version | 1 |
| evidence_summary | Extracted from wiki page mechanisms-lrrk2-kinase-pathway-parkinsons |
| evidence_xref_at | 2026-04-27T13:25:13.952301+00:00 |
| tractability_score | 0.5 |
| potential_impact_score | 0.5 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.